{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"237","value":"653"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"title":"Cycle 1 Day 2: Post Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.66","value":"14.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"155","value":"667"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Post Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.59","value":"23.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"title":"Cycle 4 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"156","value":"659"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Cycle 4 Day 1: Post Dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"PK of one pola-related analytes: acMMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG000","title":"Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL"}],"paramType":"MEAN","populationDescription":"PK evaluable population included all the ITT participants in Arm G+H (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose","title":"Arm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE","type":"SECONDARY","unitOfMeasure":"ng/mL"}